Medical Supplies Stocks' Research Reports Released on Dextera Surgical, Ekso Bionics, Endologix, and Becton, Dickinson

NEW YORK, Dec. 27, 2017 /PRNewswire/ --

WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on DXTR, EKSO, ELGX, and BDX which can be accessed for free by signing up to http://www.wallstequities.com/registration. On Tuesday, the NASDAQ Composite ended the day at 6,936.25, down 0.34%; the Dow Jones Industrial Average edged 0.03% lower, to finish at 24,746.21; and the S&P 500 closed at 2,680.50, marginally slipping 0.11%. US markets saw four out of nine sectors finishing the day in red, four in green, and one in neutral territory. WallStEquities.com has initiated research reports on the following Medical Instruments & Supplies stocks: Dextera Surgical Inc. (NASDAQ: DXTR), Ekso Bionics Holdings Inc. (NASDAQ: EKSO), Endologix Inc. (NASDAQ: ELGX), and Becton, Dickinson and Co. (NYSE: BDX). All you have to do is sign up today for this free limited time offer, click the link below. http://www.wallstequities.com/registration

Dextera Surgical

Redwood City, California-based Dextera Surgical Inc.'s stock finished Tuesday's session 8.48% higher at $0.05 with a total trading volume of 476,896 shares. Shares of the Company are trading below their 50-day moving average by 66.69%. Moreover, shares of Dextera Surgical, which designs and manufactures proprietary stapling devices for minimally invasive surgical procedures in the US, Japan, Germany, and internationally, have a Relative Strength Index (RSI) of 23.86. Get the full research report on DXTR for free by clicking below at: http://www.wallstequities.com/registration/?symbol=DXTR

Ekso Bionics Holdings

Shares in Richmond, California headquartered Ekso Bionics Holdings Inc. rose 13.15%, ending yesterday's session at $2.41 with a total trading volume of 1.84 million shares. The stock has gained 86.82% in the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 24.70% and 21.53%, respectively. Moreover, shares of Ekso Bionics, which designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America and EMEA region, have an RSI of 53.18. Gain free access to the research report on EKSO at: http://www.wallstequities.com/registration/?symbol=EKSO

Endologix

On Tuesday, Irvine, California headquartered Endologix Inc.'s stock saw a rise of 0.20%, to close the day at $5.04. A total volume of 320,905 shares was traded. The Company's shares have advanced 17.48% in the previous three months. The stock is trading below its 50-day moving average by 4.27%. Additionally, shares of Endologix, which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the US and internationally, have an RSI of 44.22.

On December 12^th, 2017, research firm Piper Jaffray resumed its 'Overweight' rating on the Company's stock. Register for your free report coverage on ELGX at: http://www.wallstequities.com/registration/?symbol=ELGX

Becton, Dickinson

Shares in Franklin Lakes, New Jersey headquartered Becton, Dickinson and Co. ended the day 0.10% lower at $217.02. A total volume of 469,912 shares was traded. The stock has gained 11.68% in the previous three months, 30.36% over the last twelve months, and 31.09% since the start of this year. The Company's shares are trading above their 200-day moving average by 9.26%. Furthermore, shares of the Company, which develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide, have an RSI of 44.74. Get the free research report on BDX at: http://www.wallstequities.com/registration/?symbol=BDX

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities